Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 15/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | F11 | P03951 | 7/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.32 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28772715 | 1.00 | CFD (0.35) | CFDMTNR1AMTNR1BF11KLKB1 | |
| SCHEMBL29852395 | 0.91 | CFD (0.40) | CFDBACE1 | |
| SCHEMBL21455663 | 0.91 | CFD (0.40) | CFDBACE1 | |
| SCHEMBL29095067 | 0.90 | CFD (0.43) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL23218573 | 0.88 | CFD (0.37) | CFDMTNR1AMTNR1BF11KLKB1 | |
| SCHEMBL29852443 | 0.88 | CFD (0.37) | CFDMTNR1AMTNR1BF11KLKB1 | |
| SCHEMBL29852925 | 0.87 | TBXAS1 (0.38) | CFDMTNR1AMTNR1BF11KLKB1 | |
| SCHEMBL23219011 | 0.87 | TBXAS1 (0.38) | CFDMTNR1AMTNR1BF11KLKB1 | |
| SCHEMBL23218235 | 0.87 | MTNR1A (0.37) | CFDMTNR1AMTNR1BF11KLKB1 | |
| SCHEMBL29853229 | 0.87 | MTNR1A (0.37) | CFDMTNR1AMTNR1BF11KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CFD 1/4885MTNR1A 3981/4885MTNR1B 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.